Pacific Edge reports steady Cxbladder test volumes

Cancer diagnostics company, Pacific Edge, has reported steady test volumes for its Cxbladder product in the third quarter of the 2025 financial year.

Total laboratory throughput rose 0.7% to 7,092 tests, while US total laboratory throughput increased 2.2% to 5,808 tests.

However, the company said it faced challenges to test volume growth, including the ongoing deliberations with Novitas and the seasonal holiday slowdown.

Despite this, the addition of a new sales team member, steady demand from US customer Kaiser Permanente, and an uplift in demand from supportive US clinicians helped mitigate the impact.

In the Asia Pacific region, test volumes were down 5.6% to 1,284 tests, attributed to the seasonal holiday slowdown in New Zealand.